drugset / Trial / NCT02919774
Pomaglumetad Effects on Glutamate Biomarkers
Phase 1
Completed
95 enrolled
New York State Psychiatric Institute
National Institute of Mental Health (NIMH) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The study will evaluate the effects of the mGluR2/3 partial agonist LY2140023 (Pomaglumetad Methionil, "POMA") at selected doses on ketamine-stimulated glutamate release in prefrontal cortex as measured by pharmacoBOLD fMRI (also termed resting BOLD fMRI).
Timeline
- Start
- 2016-10
- Primary completion
- 2018-04-28
- Completion
- 2018-05-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2140023 | Unknown | 40 mg | — |
| Subject | LY2140023 | Unknown | 160 mg | — |
Indications
No indication recorded.